Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss
Open Access
- 1 January 2013
- journal article
- review article
- Published by Wiley in Journal of Immunology Research
- Vol. 2013, 1-11
Abstract
Rheumatoid arthritis (RA) and Langerhans cell histiocytosis (LCH) are common and rare diseases, respectively. They associate myeloid cell recruitment and survival in inflammatory conditions with tissue destruction and bone resorption. Manipulating dendritic cell (DC), and, especially, regulating their half-life and fusion, is a challenge. Indeed, these myeloid cells display pathogenic roles in both diseases and may be an important source of precursors for differentiation of osteoclasts, the bone-resorbing multinucleated giant cells. We have recently documented that the proinflammatory cytokine IL-17A regulates long-term survival of DC by inducing BCL2A1 expression, in addition to the constitutive MCL1 expression. We summarize bibliography of the BCL2 family members and their therapeutic targeting, with a special emphasis on MCL1 and BCL2A1, discussing their potential impact on RA and LCH. Our recent knowledge in the survival pathway, which is activated to perform DC fusion in the presence of IL-17A, suggests that targeting MCL1 and BCL2A1 in infiltrating DC may affect the clinical outcomes in RA and LCH. The development of new therapies, interfering with MCL1 and BCL2A1 expression, to target long-term surviving inflammatory DC should be translated into preclinical studies with the aim to increase the well-being of patients with RA and LCH.Keywords
Funding Information
- Centre National de la Recherche Scientifique (2008002100, 08-MIEN-001-02)
- Institut National de la Santé et de la Recherche Médicale (2008002100, 08-MIEN-001-02)
- Université de Lyon (2008002100, 08-MIEN-001-02)
- Institut Universitaire de France (2008002100, 08-MIEN-001-02)
- Fondation Innovations en Infectiologie (2008002100, 08-MIEN-001-02)
- Fondation de France (2008002100, 08-MIEN-001-02)
- Agence Nationale de la Recherche (2008002100, 08-MIEN-001-02)
- Histiocytosis Association (2008002100, 08-MIEN-001-02)
- Ministero Sanità (2008002100, 08-MIEN-001-02)
- Progetto di Ricerca Finalizzata 2008 (2008002100, 08-MIEN-001-02)
- Associazione Italiana Ricerca Istiocitosi (2008002100, 08-MIEN-001-02)
- Swedish Children’s Cancer Foundation (2008002100, 08-MIEN-001-02)
- Vetenskapsrådet (2008002100, 08-MIEN-001-02)
- Märta och Gunnar V Philipson’s Foundation (2008002100, 08-MIEN-001-02)
- Cancer and Allergy Foundation of Sweden (2008002100, 08-MIEN-001-02)
- Karolinska Institutet (2008002100, 08-MIEN-001-02)
- Stockholm County Council (2008002100, 08-MIEN-001-02)
This publication has 81 references indexed in Scilit:
- A1/Bfl-1 in leukocyte development and cell deathExperimental Cell Research, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The Essential Role of Evasion from Cell Death in Cancer2011
- Designing Vaccines Based on Biology of Human Dendritic Cell SubsetsImmunity, 2010
- Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell AreasCell, 2010
- Bim–Bcl‐2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosisArthritis & Rheumatism, 2010
- Dendritic cells as targets for therapy in rheumatoid arthritisNature Reviews Rheumatology, 2009
- Regulatory T cells as therapeutic targets in rheumatoid arthritisNature Reviews Rheumatology, 2009
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006